Keyword: Ozempic (semaglutide)
Once it wins approval, Novo Nordisk’s semaglutide will go up against some stiff competition. But the drugmaker just showed it can take the heat.
A Bernstein analyst said media reports "misrepresent the situation."
A leading position in insulin, combined with new launches like GLP1 drug Victoza, could help Novo grow to DKK19 billion in China by 2025.
In a phase 3 study, Novo said oral semaglutide helped diabetes patients manage their blood sugar levels better than Jardiance.
Novo's Victoza lost share—again—but classwide growth boosted sales, and with doctor feedback strong for Ozempic, GLP-1 gains are ahead, analysts say.
A new report outlines 12 drugs launching this year that analysts expect to reel in big sales, with top drugmakers Roche, J&J and Gilead represented.
Novo’s semaglutide has shown it can spur weight loss in diabetic patients. Now it’s added evidence that it can help nondiabetic patients, too.
Eli Lilly is wasting no time looking for growth avenues for GLP-1 contender Trulicity. And if new data are any indication, it may have just found one.
Novo Nordisk has secured 2018 formulary coverage for Ozempic from leading U.S. pharmacy benefit manager Express Scripts.